Affiliation:
1. AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Abstract
Over the past 40 years, the search for new antibiotics has been largely restricted to well-known compound classes active against a standard set of drug targets. Although many effective compounds have been discovered, insufficient chemical variability has been generated to prevent a serious escalation in clinical resistance. Recent advances in genomics have provided an opportunity to expand the range of potential drug targets and have facilitated a fundamental shift from direct antimicrobial screening programs toward rational target-based strategies. The application of genome-based technologies such as expression profiling and proteomics will lead to further changes in the drug discovery paradigm by combining the strengths and advantages of both screening strategies in a single program.
Publisher
American Association for the Advancement of Science (AAAS)
Reference35 articles.
1. Dujon B., Trends Genet. Rev. 12, 263 (1996).
2. Basset E. B., et al., Curr. Opin. Genet. Dev. 6, 736 (1996).
3. Thomas K., FEBS Lett. 396, 1 (1996).
4. Winzeler E. A., Davies R. W., Curr. Opin. Genet. Dev. 7, 771 (1997).
5. Oliver S. G., Curr. Opin. Genet. Dev. 7, 405 (1997).
Cited by
158 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献